You have 9 free searches left this month | for more free features.

relapsed

Showing 1 - 25 of 6,556

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Nov 16, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Jul 27, 2022

Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)

Not yet recruiting
  • Relapsed/Refractory Follicular Lymphoma With EZH2
  • Shanghai, Shanghai, China
    Shanghai Cancer Center
Jul 20, 2022

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Oct 18, 2022

Relapsed Hepatoblastoma, Refractory Hepatoblastoma Trial in Cincinnati (Biospecimen collection)

Recruiting
  • Relapsed Hepatoblastoma
  • Refractory Hepatoblastoma
  • Biospecimen collection
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Sep 29, 2022

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)

Not yet recruiting
  • Relapsed/Refractory Immune Thrombocytopenia
  • Seoul, Korea, Republic of
  • +1 more
Oct 30, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Relapsed or Refractory Multiple Myeloma Trial in Dummy (Teclistamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • Dummy, France
  • +2 more
Aug 10, 2022

Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 7, 2022

Relapsed Neuroblastoma Trial in Grand Rapids (Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS))

Withdrawn
  • Relapsed Neuroblastoma
  • Cerebral Spinal (CS) radiation
  • Focal radiotherapy (SRS)
  • Grand Rapids, Michigan
    Helen DeVos Children's Hospital
Apr 20, 2022

Relapsed and Refractory B-cell Lymphoma Trial (CD19 CAR-T and CD19 CAR-DC)

Not yet recruiting
  • Relapsed and Refractory B-cell Lymphoma
  • CD19 CAR-T and CD19 CAR-DC
  • (no location specified)
Oct 16, 2022

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
May 30, 2022

Relapsed/Refractory Multiple Myeloma Trial (AMG 701)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • AMG 701
  • (no location specified)
Jun 6, 2022

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Not yet recruiting
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Aug 5, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

Recruiting
  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  • BAFFR-CAR T cells
  • Duarte, California
    City of Hope Medical Center
Jul 5, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Elotuzumab, Selinexor, and Dexamethasone (ESd)
  • (no location specified)
Apr 27, 2022

Relapsed or Advanced NSCLC Trial (Almonertinib combined with SHR-1701, Almonertinib)

Not yet recruiting
  • Relapsed or Advanced Non-small Cell Lung Cancer
  • (no location specified)
Aug 16, 2022

Relapsed and/or Refractory Multiple Myeloma Trial (CT0591CP Cells)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • CT0591CP Cells
  • (no location specified)
Aug 2, 2022